8-K: NovaBay Pharmaceuticals Faces Setback: Stockholders Reject Liquidation Plan, Company to Seek New Vote

NovaBay Pharmaceuticals' stockholders did not approve the proposed liquidation and dissolution plan at a recent meeting, prompting the company to schedule a new special meeting for another vote.

Summary

• NovaBay Pharmaceuticals held a special meeting on January 30, 2025, to vote on a proposal to liquidate and dissolve the company.
• The proposal required approval from greater than 50% of all outstanding shares, but only received approximately 49% support.
• Despite the failed vote, the board has determined that pursuing liquidation and dissolution remains the best course of action after completing the sale of substantially all assets.
• The company intends to hold a new special meeting to seek stockholder approval for the liquidation and dissolution.
• If approved, the company plans to file a Certificate of Dissolution with the Secretary of State of Delaware and proceed with liquidation, which is expected to take a minimum of nine months.
• The board reserves the right to abandon the liquidation and dissolution even if approved by stockholders if it determines it is no longer in the company's best interest.
• The company will file a new proxy statement with the SEC regarding the new special meeting.
• Distributions will be made to stockholders based on holdings as of the date the Certificate of Dissolution is filed, after which there will be limited ability to sell or transfer Company securities.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is attempting to maximize value for shareholders through liquidation, the failure of the initial vote and the uncertainty surrounding the new vote create a negative outlook. The completion of asset sales is a positive, but the overall situation indicates a winding down of the company.

Positives

• The company intends to return as much value as possible to stockholders and other stakeholders through the liquidation process.
• The company has already completed the sale of its Avenova brand and wound care assets.
• The company intends to update its stockholders, debt holders, warrant holders and preferred stockholder with additional information and written notice as the court supervised Liquidation and Dissolution progresses.

Negatives

• Stockholders did not approve the initial proposal for liquidation and dissolution.
• The liquidation process will take a minimum of nine months, during which time stockholders will not have access to any potential distributions.
• There will be limited ability to sell or transfer Company securities after the Certificate of Dissolution is filed.
• The board reserves the right to abandon the liquidation and dissolution even if approved by stockholders.

Risks

• The company may not receive stockholder approval for the liquidation and dissolution at the new special meeting.
• The board could abandon the liquidation and dissolution even if approved by stockholders.
• The liquidation process could take longer than the estimated nine months.
• The amount of value returned to stockholders may be less than expected.
• The company's ability to proceed with the Liquidation and Dissolution under Delaware law is subject to the Company first receiving stockholder approval.

Future Outlook

The company intends to hold a new special meeting to seek stockholder approval for the liquidation and dissolution, and if approved, plans to file a Certificate of Dissolution and proceed with liquidation, which is expected to take a minimum of nine months. The board reserves the right to abandon the liquidation and dissolution even if approved by stockholders.

Management Comments

• The Board, upon further analysis of the best opportunity to maximize the remaining value for the Company and its stockholders, among the other alternatives currently available, determined that it is in the best interests of the Company and its stockholders for the Company to continue pursuing the voluntary Liquidation and Dissolution pursuant to the Plan of Dissolution.

Industry Context

This announcement reflects a strategic shift for NovaBay Pharmaceuticals following the sale of its core assets, indicating a move away from active operations and towards returning value to shareholders through liquidation.

Comparison to Industry Standards

• It is difficult to compare NovaBay's situation to industry standards as the company is in the process of liquidation after selling its assets.
• Companies like Valeant (now Bausch Health) have undergone significant restructuring and asset sales, but not complete liquidation.
• The nine-month minimum timeframe for liquidation aligns with standard legal and regulatory requirements for dissolution processes in Delaware.

Stakeholder Impact

• Stockholders may receive distributions from the liquidation process, but the amount and timing are uncertain.
• Employees have likely been impacted by the sale of assets and potential liquidation.
• Creditors will be paid or provided for during the liquidation process.
• Warrant holders may receive some value consistent with the stockholder approved Plan of Dissolution.

Next Steps

• File a new proxy statement with the SEC.
• Hold a new special meeting of stockholders to vote on the liquidation and dissolution.
• If approved, file a Certificate of Dissolution with the Secretary of State of Delaware.
• Proceed with the liquidation and dissolution process, including disposing of non-cash assets, paying obligations, and distributing remaining assets.

Key Dates